Aseptic Processing

Aseptic processing carries a structural disadvantage: there is no terminal kill step. With terminal sterilisation you can sterilise the sealed final product and calculate a sterility assurance level directly. In aseptic processing the product, container, and closure are sterilised separately and then brought together — so sterility depends entirely on never introducing contamination during assembly. That is why regulators expect terminal sterilisation wherever the product can withstand it, and expect a documented justification when it cannot.

Because the operator is the dominant contamination source, control is built outward from the exposed product. The point of fill must be Grade A with unidirectional first-air protection; the background is graded according to the barrier technology; and Annex 1 (2022) now expects advanced technologies — RABS or isolators — to separate people from the critical zone in new facilities. Gowning, interventions, transfer, and airflow visualisation all exist to protect that same first air.

The 2022 revision of Annex 1 made the Contamination Control Strategy the organising document: a single, holistic assessment tying facility and equipment design, utilities, personnel, process, and monitoring into one argument for why the product will be sterile. Aseptic Process Simulation (media fill) is then the periodic test of that argument under worst-case conditions.

• —No terminal kill step — sterility depends on never introducing contamination during assembly.
• —Terminal sterilisation is expected wherever the product tolerates it; aseptic processing needs justification.
• —Point of fill is Grade A with unidirectional first air; background grade depends on the barrier used.
• —Personnel are the dominant risk — separate them by design (RABS/isolator) before relying on procedure.
• —Annex 1 (2022) requires a documented, holistic Contamination Control Strategy.
• —Media fills validate it under worst case; environmental monitoring verifies it continuously.

EU GMP Annex 1 (2022, Manufacture of Sterile Medicinal Products); FDA guidance, Sterile Drug Products Produced by Aseptic Processing — Current Good Manufacturing Practice (2004); ISO 14644-1/-2 for cleanroom classification and monitoring; PDA Technical Report No. 22 for aseptic process simulation.